Week 11. Comprehensive Study Guide: Medicare, Medicaid, and Pharmacoeconomics

Legislative History and Evolution of Medicare and Medicaid

  • 1935 Social Security Act: Marks the historical beginning of the United States federal government's direct involvement in social insurance programs.
  • 1952 Truman Health Proposal: President Harry S. Truman introduced the initial concept of Medicare. Although Truman originally advocated for an all-inclusive, universal national healthcare program, political resistance forced him to abandon that broad vision in favor of a targeted, limited health insurance program specifically designed to cover Social Security beneficiaries.
  • 1957 Congressional Action: A formal legislative bill was introduced proposing a dedicated government health insurance program for the elderly. This bill sparked nearly a decade of intense congressional debate and legislative hearings, building national consensus that elderly Americans experienced substantial barriers to securing private health insurance and that federal intervention was imperative.
  • 1965 Three-Part Legislative Compromise: Following years of sustained debate, Congress crafted a landmark three-part legislative compromise:
    • Part One: A compulsory, federally administered hospital insurance program for elderly citizens financed through mandatory payroll taxes; enacted as Medicare Part A.
    • Part Two: A voluntary, federally subsidized supplemental medical insurance program covering outpatient and physician services, financed through general federal tax revenues and enrollee premiums; enacted as Medicare Part B.
    • Part Three: A means-tested medical assistance program for low-income and impoverished individuals, administered and co-financed by individual states under broad federal standards; enacted as Medicaid.
  • Enactment of the Social Security Amendments of 1965: Signed into law by President Lyndon B. Johnson, formally establishing "Health Insurance for the Aged and Disabled" (Title XVIII for Medicare and Title XIX for Medicaid).
  • Medicaid's Inception and Political Realignment: Medicaid was incorporated as a last-minute addition to the 1965 legislative package without comprehensive actuarial forecasts or cost projections. Contemporaries widely viewed Medicaid as a temporary stopgap, predicting that a subsequent Democratic presidential victory would transition the nation toward universal healthcare. That policy trajectory stalled with the 1968 election of President Richard Nixon, solidifying the state-federal dual structure.

Medicare Program Structure, Governance, and Quality Star Ratings

  • Original Structural Divisions (1965):
    • Medicare Part A: Hospital Insurance (HI) covering inpatient hospital stays, skilled nursing facility care, hospice care, and home health services.
    • Medicare Part B: Supplementary Medical Insurance (SMI) covering physician services, outpatient hospital care, durable medical equipment, and select preventive services.
  • Subsequent Structural Expansions:
    • Medicare Part C (Medicare Advantage): Enacted under the Balanced Budget Act of 1997 to expand beneficiary options by allowing private managed care organizations—including Health Maintenance Organizations (HMOs) and Preferred Provider Organizations (PPOs)—to deliver Medicare benefits.
    • Medicare Part D (Prescription Drug Benefit): Established under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) to provide outpatient prescription drug coverage, taking effect in 2006.
  • Administrative and Operational Governance:
    • U.S. Department of Health and Human Services (HHS): Exercises primary cabinet-level oversight and legal responsibility for the entire Medicare program.
    • Social Security Administration (SSA): Processes Medicare beneficiary eligibility determinations and handles initial and ongoing program enrollment.
    • Centers for Medicare and Medicaid Services (CMS): Operates as the HHS operational agency managing policy development, day-to-day operations, provider reimbursement, and regulatory oversight.
    • U.S. Department of the Treasury: Administers and safeguards the two statutory trust funds: the Hospital Insurance (HI) Trust Fund and the Supplementary Medical Insurance (SMI) Trust Fund.
    • Conditions of Participation (CoP): Federal health and safety standards that healthcare facilities and clinicians must comply with to qualify for Medicare reimbursement; state government agencies assist CMS by surveying and certifying provider compliance.
    • Claims Administrators / Medicare Administrative Contractors (MACs): Private fiscal entities (such as Blue Cross Blue Shield organizations) that contract directly with CMS to adjudicate, process, and pay Part A and Part B medical claims submitted by providers.
  • Medicare Star Ratings System:
    • Rating Scale: Evaluates Medicare Part C (Medicare Advantage) and Part D (Prescription Drug) plans using an objective scale ranging from 11 to 55 stars, where 1 star1\text{ star} denotes poor performance and 5 stars5\text{ stars} reflects excellence.
    • Evaluation Domains for Health Plans (Medicare Advantage):
    • Staying healthy (screenings, tests, and vaccines)
    • Managing chronic (long-term) conditions
    • Member experience and plan ratings
    • Member complaints and changes in plan performance
    • Customer service
    • Evaluation Domains for Drug Plans (Part D):
    • Customer service
    • Member complaints and changes in drug plan performance
    • Member experience and plan satisfaction
    • Drug safety and accuracy of drug pricing
    • Incentive Structure: Plans earning higher star ratings receive substantial competitive advantages, including expanded year-round marketing privileges and direct financial bonus payments from CMS.

Medicare Beneficiary Eligibility and Trust Fund Financing

  • Program Size and Demographics: Medicare provides health coverage to approximately 67.5 million67.5\text{ million} total beneficiaries. The elderly population comprises 89.5%89.5\% of all enrollees (individuals aged 65 years65\text{ years} and older), while the remaining 10.5%10.5\% consists of non-elderly individuals qualifying through qualifying disabilities or specific medical conditions.
  • Part A Eligibility Criteria:
    • Automatic Premium-Free Eligibility at Age 6565 or Older: Conferred if the individual satisfies either of two conditions:
    • Entitled to or actively receiving retirement benefits from the Social Security Administration or the Railroad Retirement Board.
    • Has accumulated sufficient Medicare-covered government employment credits.
    • Premium-Purchased Part A at Age 6565 or Older: Individuals who fail to meet work-credit requirements may purchase Part A coverage by paying a monthly premium.
    • Eligibility Prior to Age 6565 (Premium-Free):
    • Conferred after receiving Social Security or Railroad Retirement Board disability cash benefits for a minimum qualifying period of 24 months24\text{ months}.
    • Amyotrophic Lateral Sclerosis (ALS) Exception: Beneficiaries diagnosed with ALS have the statutory 24 month24\text{ month} disability waiting period waived immediately upon entitlement to disability benefits.
    • End-Stage Renal Disease (ESRD) Exception: Individuals diagnosed with permanent kidney failure requiring ongoing maintenance dialysis or a kidney transplant qualify for coverage regardless of age.
  • Part B Eligibility Criteria:
    • Enrollment in Part B is strictly voluntary and requires payment of a monthly premium (typically deducted directly from monthly Social Security benefit checks).
    • Any individual eligible for premium-free Part A is entitled to enroll in Part B.
    • Individuals aged 6565 or older who do not qualify for premium-free Part A must satisfy three legal standards to enroll in Part B:
    • Be aged 6565 or older.
    • Reside within the United States.
    • Be a U.S. citizen, or a lawfully admitted permanent resident alien who has resided continuously in the United States for at least 5 years5\text{ years}.
  • Statutory Financing Architecture:
    • Part A Financing: Paid through the Hospital Insurance (HI) Trust Fund. Funded primarily by a dedicated mandatory payroll tax of 2.9%2.9\% levied on all covered earnings (split evenly as 1.45%1.45\% paid by the employee and 1.45%1.45\% paid by the employer; self-employed individuals pay the full 2.9%2.9\%). Beneficiary cost sharing (deductibles, coinsurance, and purchaser premiums) provides supplementary revenue. Under federal law, higher-income earners pay an additional higher payroll tax rate.
    • Part B Financing: Paid through the Supplementary Medical Insurance (SMI) Trust Fund. Financed predominantly (≈75%\approx 75\%) through general revenues of the federal government, with the remaining balance funded by beneficiary monthly premiums, trust fund interest, and miscellaneous receipts. Higher-income beneficiaries are assessed higher monthly premiums via income-related monthly adjustment amounts.
    • Part C Financing: Does not maintain a separate dedicated trust fund. Funding is drawn proportionately from the Hospital Insurance Trust Fund (for Part A-equivalent benefits) and the Supplementary Medical Insurance Trust Fund (for Part B- and Part D-equivalent benefits), supplemented by beneficiary premiums.
    • Part D Financing: Financed through a combination of federal general revenues, monthly beneficiary premiums, and mandatory state "clawback" payments submitted on behalf of dual-eligible beneficiaries (individuals qualifying for both Medicare and Medicaid). Higher-income enrollees pay higher monthly Part D premiums.

Medicare Part A Covered Services, Benefit Periods, and Cost Sharing

  • The Inpatient Hospital Benefit Period:
    • Definition: A benefit period (also known as a spell of illness) commences on the first day a beneficiary is admitted as an inpatient into a hospital and concludes once the beneficiary has remained out of any hospital or skilled nursing facility for 60 consecutive days60\text{ consecutive days}.
    • Nursing Home Rule: The benefit period also terminates if a patient resides inside a nursing facility for 60 consecutive days60\text{ consecutive days} without receiving skilled nursing or skilled rehabilitative care.
    • Frequency and Lifetime Limits: An individual may experience multiple distinct benefit periods within a single calendar year; there is no lifetime limit on the total number of benefit periods a beneficiary may use.
  • Inpatient Hospital Services Coverage and Patient Cost Sharing (2025 Rates):
    • Part A covers up to 90 days90\text{ days} of medically necessary inpatient hospital care within each individual benefit period.
    • Days 11 through 6060: The beneficiary is responsible for a one-time inpatient deductible of $1,676\$1,676 per benefit period. If an individual is hospitalized multiple times within the same 60-day60\text{-day} window without exhausting 6060 total days of care, no additional deductible is charged.
    • Days 6161 through 9090: The beneficiary pays a daily copayment of $419 per day\$419\text{ per day}, which is set by law at exactly one-fourth (14\frac{1}{4}) of the inpatient hospital deductible ($1,6764=$419\frac{\$1,676}{4} = \$419).
    • Lifetime Reserve Days: Beneficiaries maintain a non-renewable bank of 6060 lifetime reserve days to cover hospitalizations extending beyond 90 days90\text{ days} in a single benefit period. The copayment for lifetime reserve days is $838 per day\$838\text{ per day}, set at exactly one-half (12\frac{1}{2}) of the inpatient hospital deductible ($1,6762=$838\frac{\$1,676}{2} = \$838).
    • Scope of Hospital Services Covered: Semi-private rooms, regular meals, general nursing care, operating and recovery room services, clinical laboratory tests, X-rays, and emergency department services.
    • Blood Deductible: The beneficiary must either pay out-of-pocket for or donate to replace the first 3 pints3\text{ pints} of whole blood or units of packed red blood cells utilized each calendar year. Replacement can be performed by the patient or donated by another individual on their behalf.
  • Skilled Nursing Facility (SNF) Care:
    • Eligibility Requirements: The beneficiary must require daily skilled nursing care or skilled rehabilitative therapy services that, as a practical matter, can only be administered inside an institutional inpatient SNF. Pure custodial care (assistance with activities of daily living such as dressing, eating, bathing, toileting, or routine medication administration) does not qualify.
    • Prior Hospitalization Mandate: The SNF admission must be preceded by a qualifying medically necessary inpatient hospital stay of at least 3 consecutive days3\text{ consecutive days} (not counting the day of discharge) and must occur within 30 days30\text{ days} of hospital discharge.
    • Benefit Limits and Covered Services: Up to 100 days100\text{ days} of SNF care per benefit period. Covers semi-private room accommodations, nursing care, meals, prescription medications, medical supplies, appliances, physical therapy (PT), occupational therapy (OT), and speech-language pathology services.
    • SNF Cost Sharing (2025 Rates):
    • Days 11 through 2020: $0\$0 copayment (covered fully by Medicare Part A).
    • Days 2121 through 100100: Daily copayment of $209.50 per day\$209.50\text{ per day}, which equals one-eighth (18\frac{1}{8}) of the inpatient hospital deductible ($1,6768=$209.50\frac{\$1,676}{8} = \$209.50).
    • Days 101101 and beyond: The patient is responsible for 100%100\% of all costs.
  • Home Health Care Services:
    • Purpose: Structured as short-term recovery and restorative support following an illness or injury, rather than ongoing long-term custodial care.
    • Service Limits: Covers up to a maximum of 100 home health visits100\text{ home health visits} following a qualifying inpatient hospital stay or SNF stay of at least 3 consecutive days3\text{ consecutive days}. Visits exceeding this threshold transition to Part B coverage.
    • Prerequisites: Beneficiaries must require intermittent skilled nursing care, physical therapy, occupational therapy, or speech-language pathology.
    • Ancillary Services Included: Home health aide services, medical social services, and routine medical supplies.
    • Cost Sharing: Covered at 100%100\% with no deductible or coinsurance, with the exception of durable medical equipment (DME), which carries a mandatory 20%20\% coinsurance payment.
  • Hospice Care Services:
    • Eligibility: The beneficiary must be diagnosed with a terminal illness carrying a certified physician prognosis of a life expectancy of 6 months6\text{ months} or less if the disease runs its normal course.
    • Scope of Benefits: Physician services, skilled nursing, physical and occupational therapy, medical social work, psychological and spiritual counseling, homemaker services, specialized pain management, and palliative symptom relief.
    • Respite Care: Covers short-term inpatient respite care up to 5 consecutive days5\text{ consecutive days} in a Medicare-certified nursing facility or hospital to provide relief for family caregivers.
    • Cost Sharing: Beneficiaries pay nominal coinsurance for outpatient prescription drugs prescribed for palliative symptom relief and a 5%5\% coinsurance for inpatient respite care stays.

Medicare Part B Covered Services, Exclusions, and Provider Assignment

  • Scope of Covered Services:
    • Professional Services: Physician services delivered across all healthcare settings (inpatient hospitals, outpatient clinics, private offices, nursing facilities, and patient homes). In an inpatient surgical admission, Part A reimburses the hospital facility fees, while Part B reimburses the surgeon's professional service fees.
    • Non-Physician Practitioners: Professional services delivered by licensed Physician Assistants (PAs), Nurse Practitioners (NPs), and Certified Registered Nurse Anesthetists (CRNAs).
    • Outpatient and Diagnostic Services: Outpatient hospital facility care, clinical laboratory testing, diagnostic imaging (X-rays), outpatient physical and occupational therapy, home health care beyond Part A limits, outpatient dialysis services, and emergency ambulance transportation.
    • Specialized Pharmaceutical Coverage: Injectable and infused medications not typically self-administered by patients (administered in clinics or physician offices), post-transplant immunosuppressive medications, and specific oral anti-cancer agents.
    • Durable Medical Equipment (DME): Wheelchairs, hospital beds, oxygen concentrators, and walkers.
    • Preventive Health Services: Cardiovascular screenings, diabetes screenings, bone mass density scans, mammograms, colorectal cancer screenings, and annual wellness examinations.
    • Limited Specialized Services: Medically necessary services provided by chiropractors (manual manipulation of the spine), podiatrists, optometrists, and dental surgeons (complex facial/jaw surgeries).
  • Statutory Coverage Exclusions:
    • Routine annual physical examinations
    • Routine vision examinations and eyeglasses
    • Hearing examinations and hearing aids
    • Routine dental care, cleanings, and dentures
  • Part B Cost Sharing Architecture (2025 Rates):
    • Annual Deductible: $257 per year\$257\text{ per year}.
    • Standard Coinsurance: Once the annual deductible is satisfied, Medicare reimburses 80%80\% of the Medicare-approved charge, and the patient is responsible for the remaining 20%20\% coinsurance.
  • Provider Assignment and Billing Protections:
    • Medicare Approved Charge: The maximum allowable fee established by CMS for a specific medical service code.
    • Participating Physicians (Accepting Assignment): Clinicians who sign a participation agreement agreeing to accept the Medicare-approved charge as payment in full. These providers are legally barred from "balance billing" the patient for amounts exceeding the approved rate. In exchange, CMS reimburses participating physicians at rates approximately 5%5\% higher than non-participating physicians.
    • Non-Participating Physicians (Not Accepting Assignment): Clinicians who decline assignment may bill the patient directly. However, under federal limiting charge statutes, non-participating providers are strictly prohibited from charging more than 115%115\% of the Medicare-approved amount (Limiting Charge=1.15×Approved Charge\text{Limiting Charge} = 1.15 \times \text{Approved Charge}). The patient remains responsible for the 20%20\% coinsurance plus any balance up to the 115%115\% statutory cap.

Medicare Advantage (Part C) and Prescription Drug Coverage (Part D)

  • Medicare Part C (Medicare Advantage):
    • Enrollment Magnitude: Established in 1997, enrollment grew to 33 million33\text{ million} beneficiaries in 2024, representing 54%54\% of the entire eligible Medicare population.
    • Plan Models: Administered by private commercial insurers operating primarily as Health Maintenance Organizations (HMOs) or Preferred Provider Organizations (PPOs).
    • Actuarial Equivalence: Private plans are legally required to provide a comprehensive benefit package that is actuarially equivalent to, or more generous than, original fee-for-service Medicare (Parts A and B).
    • Rebate and Savings Distribution: When private plan operating costs fall below CMS benchmark payment rates, plans must return the savings to enrollees in the form of reduced premiums, lowered cost sharing, or supplementary benefits (e.g., dental, vision, hearing), or return the excess funds to Medicare.
  • Medicare Part D (Prescription Drug Benefit):
    • Enrollment Magnitude: Began operations in 2006; currently covers approximately 54 million54\text{ million} beneficiaries, which accounts for roughly 80%80\% of all Medicare recipients.
    • Delivery Pathways:
    • Stand-alone Prescription Drug Plans (PDPs): Purchased by beneficiaries who choose to remain in traditional fee-for-service Medicare.
    • Medicare Advantage Prescription Drug Plans (MA-PDs): Integrated managed care plans combining Part A, Part B, and prescription drug benefits.
    • Benefit Parameters and Cost-Sharing Mechanisms:
    • Beneficiaries pay a monthly plan premium (adjusted upward for higher incomes).
    • Statutory Maximum Deductible (2025): Capped at $590\$590. Plans may offer zero-dollar deductibles or apply deductibles exclusively to higher-cost tiers.
    • Tiered copayments or percentage coinsurance apply to formulary tiers (e.g., preferred generic, non-preferred generic, preferred brand, non-preferred brand, specialty).
    • Utilization control tools: Formularies, step therapy, prior authorizations, and quantity limits.
    • Inflation Reduction Act (IRA) Reforms:
    • Elimination of the Coverage Gap (Donut Hole): Effective in 2025, the historical coverage gap—where beneficiaries previously faced high out-of-pocket expenses after exceeding an initial spend threshold until reaching catastrophic thresholds—is fully abolished.
    • Annual Out-of-Pocket Cap (2025): Establishes a hard annual out-of-pocket maximum of $2,000\$2,000 for covered prescription medications. Once a beneficiary incurs $2,000\$2,000 in out-of-pocket drug expenses, catastrophic coverage takes effect immediately: Medicare covers 100%100\% of drug costs, and the enrollee pays $0\$0 for the remainder of the calendar year.
    • Extra Help / Low-Income Subsidy (LIS) Program: Federal assistance providing subsidized monthly premiums, waived or low deductibles, and nominal prescription copayments for low-income beneficiaries.
    • Medicare Drug Price Negotiation Program:
    • Authorizes CMS to negotiate directly with pharmaceutical manufacturers to set a "Maximum Fair Price" (MFP) on high-expenditure, single-source brand-name drugs.
    • First Cohort of Negotiated Drugs (10 Drugs, Effective 2026):
      • Eliquis (apixaban)
      • Jardiance (empagliflozin)
      • Xarelto (rivaroxaban)
      • Januvia (sitagliptin; transcribed as Janubia)
      • Farxiga (dapagliflozin)
      • Entresto (sacubitril/valsartan)
      • Enbrel (etanercept)
      • Imbruvica (ibrutinib; transcribed as Ibrubica)
      • Stelara (ustekinumab)
      • Fiasp and NovoLog (insulin aspart; transcribed as Fiasp and Obalog)
    • Financial Impact of the Initial 10 Drugs: In 2022, these ten pharmaceuticals accounted for $50.5 billion\$50.5\text{ billion} in gross Medicare spending (≈20%\approx 20\% of Medicare's total gross drug expenditures) and cost beneficiaries $3.4 billion\$3.4\text{ billion} in direct out-of-pocket expenses. Negotiated maximum fair prices represent statutory discounts ranging from 38%38\% to 79%79\% off list prices.
    • Expansion Schedule for Drug Price Negotiations:
      • 1515 additional Part D drugs selected in 2025 (effective 2027)
      • 1515 additional Part B and Part D drugs selected in 2026 (effective 2028)
      • 2020 additional Part B and Part D drugs selected in 2027 (effective 2029)
      • 2020 additional Part B and Part D drugs selected in 2028 and every year thereafter

Medicare Long-Term Expenditure Trends and Medigap Supplemental Insurance

  • Long-Term Program Expenditure Growth:
    • Enrollment Trajectory: Total Medicare enrollment expanded from 19 million19\text{ million} beneficiaries in 1970 to 67.5 million67.5\text{ million} in 2023.
    • Financial Outlays: Aggregate federal program spending surged from $7.5 billion\$7.5\text{ billion} in 1970 to over $1 trillion\$1\text{ trillion} ($1,000,000,000,000\$1,000,000,000,000) in 2023.
    • Future Projections: Program expenditures are projected to surpass $1.8 trillion\$1.8\text{ trillion} ($1,800,000,000,000\$1,800,000,000,000) by the year 2031.
    • Primary Cost Drivers: A rapidly expanding aging demographic (the aging baby-boom cohort entering Medicare eligibility) paired with steep medical cost inflation.
  • Shifts in Spending Across Medicare Components:
    • Part B Expansion: Spending on Part B grew from 41%41\% of total Medicare benefit outlays in 2011 to 48%48\% in 2021, becoming the largest programmatic expenditure category. This trend reflects the systemic clinical shift of procedures, diagnostic evaluations, and chemotherapy regimens from inpatient hospital environments to outpatient facilities.
    • Part A Contraction: Part A spending decreased as a relative percentage of total program outlays, directly mirroring reduced inpatient lengths of stay and the migration toward outpatient care.
    • Part D Stability: Part D drug expenditures remained relatively constant as a proportion of total outlays from 2011 to 2021, though the long-term cost impacts of the Inflation Reduction Act price negotiations and benefit restructuring remain under ongoing evaluation.
  • Medicare Supplement (Medigap) Insurance:
    • Function: Standardized private insurance policies designed to pay for the out-of-pocket cost-sharing requirements inherent in traditional fee-for-service Medicare (e.g., deductibles, copayments, and coinsurance).
    • Standardized Benefit Packages: State insurance commissioners regulate Medigap plans under standardized alphabetical plan designs ranging from Plan A through Plan N.
    • Plan A (Core Package): The fundamental statutory baseline policy that must be approved for sale in every state and offered by all private Medigap carriers. Covers:
    • Part A inpatient hospital coinsurance and hospital costs for an additional 365 days365\text{ days} after exhausting Medicare lifetime reserve days
    • Part B coinsurance or copayments (20%20\% of approved charges)
    • Part A hospice care copayments or coinsurance
    • The first 3 pints3\text{ pints} of blood deductible
    • Additional Medigap Plans (Plans B through N): Offer varying combinations of supplemental coverages, including skilled nursing facility daily copayments (Days 21–100), the Part A hospital deductible, the Part B deductible, and foreign travel emergency healthcare coverage.

Medicaid Eligibility Criteria, Administration, and Financing Structure

  • Foundational Program Design: Medicaid is a joint federal and state program designed to provide medical assistance to eligible low-income individuals and families. The program operates as an open-ended federal entitlement grant to states.
  • Impact of the Affordable Care Act (ACA):
    • Medicaid Expansion: Granted states the legal option to expand Medicaid eligibility to non-elderly adults and children with household incomes at or below 133%133\% of the Federal Poverty Level (FPL) (with a statutory 5%5\% income disregard, effectively setting the threshold at 138%138\% FPL).
    • Standardized Income Assessment: Established the Modified Adjusted Gross Income (MAGI) standard to determine financial eligibility across populations, standardizing income calculations across participating states.
  • The Three Primary Medicaid Eligibility Categories:
    • Mandated Categorically Needy: Populations that federal law compels all participating state programs to cover:
    • Low-income families with children meeting historical cash-assistance benchmarks
    • Pregnant women and children under age 66 living in households with incomes at or below federal statutory minimums
    • Children aged 66 through 1818 living in families with incomes below 100%100\% of the FPL
    • Qualified low-income elderly, blind, or disabled individuals receiving cash assistance under the Supplemental Security Income (SSI) program
    • Qualified Medicare Beneficiaries (QMBs): Low-income Medicare recipients whose incomes and assets fall below federal limits, for whom Medicaid pays Medicare Part A and B premiums, deductibles, and coinsurance
    • Optional Categorically Needy: Demographic groups that states may elect to cover; if covered, they must receive the identical comprehensive benefit package provided to the mandated categorically needy group. These individuals do not meet standard categorical cash assistance benchmarks but share comparable demographic characteristics (primarily low-income infants, children, and pregnant women above baseline income limits).
    • Medically Needy: An optional state program classification covering individuals whose income and financial assets exceed standard Medicaid income ceilings, but who suffer from catastrophic or severe medical conditions. Enrollees qualify by "spending down" their excess income on high out-of-pocket medical bills until their remaining net income falls below state-established medically needy income thresholds. Most states opt to operate Medically Needy programs covering families, children, elderly persons, and disabled individuals.
  • Program Administration and Governance:
    • Federal Role: CMS establishes broad statutory guidelines, approves State Plan Amendments (SPAs), issues program waivers, and distributes federal matching funds. Participation is voluntary for states, but all 50 states50\text{ states}, territories, and the District of Columbia operate active Medicaid programs.
    • State Role: Each state must designate a "Single State Agency" charged with administering the program. This state agency establishes specific eligibility thresholds, defines the scope and duration of covered services, formulates provider reimbursement rate methodologies, and manages daily claims administration.
  • Medicaid Financing Architecture and Federal Matching:
    • Federal Medical Assistance Percentage (FMAP): The statutory formula determining the share of state Medicaid provider claims paid by the federal government. Recalculated annually for each state by comparing the state's average per capita income to the national per capita income average.
    • FMAP Statutory Range: Federal law establishes a statutory floor of 50%50\% and a statutory ceiling of 83%83\% (50%≤FMAP≤83%50\% \le \text{FMAP} \le 83\%). Wealthier states with higher per capita incomes receive the baseline 50%50\% federal match, whereas lower-income states receive substantially higher federal matching rates.
    • Provider Billing Protections: Balance billing is strictly prohibited by federal law. Providers who treat Medicaid enrollees must accept the established Medicaid reimbursement fee as payment in full and cannot bill the patient for the difference between their billed charges and Medicaid payments.
    • Payment Adequacy Standards: Federal regulations mandate that state reimbursement rates must be sufficient to attract enough participating healthcare providers to ensure that care is available to Medicaid enrollees to the same extent as the general population in the geographic area, while prohibiting reimbursement rates from exceeding what Medicare would pay for equivalent services.

Medicaid Mandatory and Optional Benefits, Cost-Sharing, and Delivery Innovation

  • Mandatory Medicaid Benefits (Required for Federal Matching Funds):
    • Inpatient hospital services
    • Outpatient hospital services
    • Physician services
    • Rural Health Clinic (RHC) services
    • Federally Qualified Health Center (FQHC) services
    • Laboratory and diagnostic X-ray services
    • Nursing facility services for adults aged 2121 and older
    • Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) services for enrollees under age 2121
    • Family planning services and reproductive health supplies
    • Certified nurse-midwife services
    • Pediatric and family nurse practitioner services
    • Freestanding birth center services
    • Home health services for individuals entitled to nursing facility care
    • Tobacco cessation counseling and pharmacotherapy for pregnant women
    • Medication-Assisted Treatment (MAT) for opioid use disorder
    • Non-emergency medical transportation (NEMT) to facilitate access to care
  • Optional Medicaid Benefits: Services states may elect to cover, including dental services, physical therapy, optometry and eyeglasses, prosthetic devices, and prescription drugs. Although outpatient prescription drug coverage is technically classified as an optional benefit under federal law, all 50 states50\text{ states} choose to include prescription drug coverage within their Medicaid programs.
  • Patient Cost Sharing Regulations:
    • States may implement nominal cost sharing (deductibles, copayments, or coinsurance), provided cost sharing does not impose a financial barrier preventing enrollees from accessing necessary care.
    • Prescription Drug Copayments: Where utilized, prescription copayments are nominal, typically ranging from $0.50\$0.50 to $3.00\$3.00.
    • Exempt Populations and Services: Federal statute strictly prohibits cost sharing on emergency department services, family planning services, pregnancy-related care, and all healthcare services delivered to children.
  • Enrollment Magnitude and Expenditure Dynamics:
    • Enrollment Growth: Medicaid enrollment expanded from 17.6 million17.6\text{ million} individuals in 1972 to 77.7 million77.7\text{ million} in 2025. Program enrollment peaked at approximately 94 million94\text{ million} during the COVID-19 Public Health Emergency due to statutory continuous-enrollment provisions that paused routine eligibility redeterminations from 2020 through 2023. Current enrollment remains higher than pre-pandemic 2020 levels.
    • Financial Outlays: Total aggregate Medicaid spending escalated from less than $10 million\$10\text{ million} in 1972 to $909 billion\$909\text{ billion} in 2024.
    • Disproportionate Spending Distribution Across Enrollees:
    • Children: Account for more than two-fifths (>40%>40\%) of all Medicaid enrollees, but generate only one-fifth (≈20%\approx 20\%) of total program expenditures.
    • Elderly and Disabled Individuals: Account for only one-fifth (≈20%\approx 20\%) of total Medicaid enrollees, but consume nearly half (≈50%\approx 50\%) of all Medicaid program spending due to extensive institutional nursing care, home- and community-based long-term services, and complex chronic disease management.
  • State Programmatic Requirements and CMS Waivers:
    • The Three Traditional Core Medicaid Mandates:
    • Statewideness: Mandatory services covered by a state must be uniformly available across the entire geographic territory of the state.
    • Freedom of Choice: Beneficiaries must be permitted to obtain covered care from any qualified provider participating in Medicaid.
    • Comparability of Services: The amount, duration, and scope of covered services must be equal across all categorically eligible beneficiaries.
    • CMS Innovation Waivers:
    • Section 1115 Demonstration Waivers: Permits states to operate statewide demonstration projects designed to test new delivery models, expand coverage to non-traditional populations, and test policy innovations.
    • Managed Care Waivers: Waives freedom-of-choice rules to permit states to enroll beneficiaries into mandatory Medicaid Managed Care Organizations (MCOs).
    • Dominance of Managed Care: Managed care represents the dominant delivery model, with approximately 70%70\% of all Medicaid beneficiaries enrolled in private MCOs.

Comparative Analysis: Medicare Social Insurance versus Medicaid Public Welfare

  • Structural and Systemic Similarities:
    • Both programs represent large-scale, government-financed health coverage systems overseen at the federal level by CMS.
    • Both serve comparable populations (67.5 million67.5\text{ million} Medicare enrollees versus 77.7 million77.7\text{ million} Medicaid enrollees).
    • Both consume comparable financial resources (>\n\$1\text{ trillion} for Medicare versus $909 billion\$909\text{ billion} for Medicaid).
    • Both operate as vital safety-net programs providing essential medical care to selected segments of American society.
  • Operational and Administrative Divergences:
    • Financing: Medicare is financed primarily through federal payroll taxes, federal general revenues, and monthly enrollee premiums; Medicaid is financed through shared state general funds and federal matching grants (FMAP).
    • Administration: Medicare is a single, nationally uniform federal program administered directly by CMS; Medicaid is administered as 5050 distinct state-level programs operating within broad federal parameters.
    • Eligibility: Medicare eligibility is primarily tied to age (65+65+), long-term disability, or specific diagnoses (ESRD, ALS); Medicaid eligibility is strictly contingent upon income and resource thresholds (means testing).
    • Scope of Long-Term Care: Medicare provides strictly time-limited acute post-hospital restorative care (up to 100 days100\text{ days} in an SNF) and excludes custodial care; Medicaid serves as the primary national payer for custodial nursing home care and long-term community supports.
  • Philosophical Divergence:
    • Medicare: Grounded in a social insurance philosophy. Beneficiaries earn an entitlement to benefits by working and paying dedicated payroll taxes throughout their careers.
    • Medicaid: Grounded in a public welfare and wealth redistribution philosophy. Financed through general tax revenues to deliver medical assistance based entirely on financial need, with no requirement of prior work contribution.

Theoretical Foundations and Core Principles of Pharmacoeconomics

  • Definition of Pharmacoeconomics: A specialized field of health economics compiling methodologies that identify, measure, and compare the economic, clinical, and humanistic outcomes (ECHO model) of pharmaceutical products and services. Pharmacoeconomic research directly compares the inputs (resources consumed) to the outputs and outcomes generated by drug therapies and clinical pharmacy services.
  • Historical Development: Pharmacoeconomics emerged during the 1970s by adopting analytical tools and methodologies from public finance economics, driven by escalating healthcare expenditures and the necessity to demonstrate economic value in clinical decision-making.
  • Practical Applications in Health Systems and Managed Care:
    • Selecting pharmaceutical products for hospital and health system formulary inclusion
    • Formulating evidence-based clinical practice guidelines
    • Designing and monitoring disease state management programs
    • Structuring prior authorization (PA) protocols
    • Establishing step therapy ("fail-first") clinical requirements
    • Designing tiered prescription drug benefits for commercial insurers and Medicare Part D
  • Core Conceptual Elements (Inputs, Outputs, and Outcomes):
    • Inputs: The direct and indirect economic resources consumed to provide a healthcare product or intervention (quantified as costs in monetary terms).
    • Outputs: The immediate physical product or clinical service generated from those resources (e.g., number of patients treated, pharmacy consultations provided, or prescription units dispensed).
    • Outcomes: The ultimate clinical, economic, or humanistic consequences achieved from providing the product or service (e.g., lives saved, blood pressure lowered, quality of life improved, or hospitalizations avoided).
  • Contrasting Efficiency, Efficacy, and Effectiveness:
    • Efficiency: The production of a good or service at the lowest possible cost per unit of output (InputsOutputs\frac{\text{Inputs}}{\text{Outputs}}). Often characterized as obtaining the "biggest bang for the healthcare buck."
    • Cost-Effectiveness: The achievement of the desired healthcare outcome at the lowest possible cost, linking inputs directly through outputs to ultimate outcomes (InputsOutputs→Outcomes\frac{\text{Inputs}}{\text{Outputs} \rightarrow \text{Outcomes}}).
    • Efficacy: Evaluates whether an intervention produces a favorable therapeutic result under ideal, tightly controlled experimental conditions (such as a double-blind randomized clinical trial). Directly answers the question: Does the product work under ideal conditions, and does it do more good than harm?
    • Effectiveness: Evaluates whether an intervention produces therapeutic benefit when deployed in routine clinical practice across real-world, unselected patient populations. Directly answers the question: Does the product work in the real-world patients it was designed to treat?
  • Five-Step Framework for Conducting a Pharmacoeconomic Evaluation:
    • Step 1: Define the Problem and State the Objective: Articulate a precise, concise research question (e.g., Is the addition of infliximab cost-effective compared to standard therapy for the treatment of Crohn's disease in patients failing standard non-biologic agents?).
    • Step 2: Identify the Perspective: Establish the economic viewpoint from which costs and consequences will be evaluated. Common perspectives include the healthcare payer (commercial insurer or CMS), the patient, the self-insured employer, the hospital/health system, or society as a whole.
    • Step 3: Identify Alternative Interventions: Select the relevant therapeutic competitors for comparison (e.g., drug versus drug, drug versus surgical intervention, or drug therapy versus standard supportive care/no treatment).
    • Step 4: Identify and Measure Outcomes: Determine and quantify the relevant clinical, humanistic, or economic consequences produced by each alternative (e.g., disease cure, morbidity reduction, life-years gained, quality of life changes, or adverse event rates).
    • Step 5: Identify, Measure, and Value Costs: Identify all resources consumed, measure resource utilization in physical units, and assign appropriate monetary values to those resources.

Cost Categorization, Valuation, and Methodological Considerations

  • The Four Core Categories of Healthcare Costs:
    • Direct Medical Costs: Resources consumed for medical goods and clinical services directly related to the intervention being evaluated. Typically borne by third-party healthcare payers and patients via cost sharing. Examples include:
    • Physician office visits
    • Emergency department visits
    • Diagnostic laboratory and radiological testing
    • Prescription medications
    • Inpatient hospital admissions
    • Surgical procedures
    • Direct Non-Medical Costs: Non-medical economic resources consumed as a direct consequence of seeking or receiving healthcare services. Rarely reimbursed by third-party payers and generally paid out-of-pocket by patients and families. Examples include:
    • Transportation expenses to and from medical appointments (gas, parking, bus/train fares, ambulance fees)
    • Specialized therapeutic dietary requirements
    • Specialized physical exercise or home rehabilitation equipment
    • Childcare or eldercare costs incurred while attending medical appointments
    • Indirect Costs: Costs resulting from morbidity and premature mortality that reduce economic productivity. Borne by patients, families, employers, and society. Highly controversial due to difficulties in establishing direct causal links and measuring output loss. Examples include:
    • Lost work time (absenteeism)
    • Decreased on-the-job productivity due to illness (presenteeism)
    • Early retirement or premature workforce departure due to chronic disability
    • Foregone future earnings resulting from premature death
    • Intangible Costs: The non-monetary, physical and emotional toll resulting from disease or its treatment. Intangible costs are very real to patients but remain challenging to monetize in economic evaluations. Examples include:
    • Physical pain and suffering
    • Psychological anxiety, stress, and clinical depression
    • Loss of physical autonomy
    • Treatment-induced fatigue, nausea, or disfigurement
  • Methodological Rules for Measuring and Valuing Costs:
    • Relevant Costs: A relevant cost is one that would not have been incurred if not for the therapeutic product or service under evaluation.
    • Cost Savings versus Cost Shifting: Researchers must differentiate genuine reductions in aggregate resource consumption (true cost savings) from scenarios where financial burdens are simply transferred from one stakeholder to another (cost shifting, e.g., an insurer shifting medication costs onto patients via higher deductibles).
    • Resource Measurement: Quantifying resource consumption in physical units (e.g., hours of nursing care, number of physician visits, or inpatient days).
    • Resource Valuation: Assigning appropriate monetary values to consumed resources using prices, reimbursement fee schedules, or cost-to-charge ratios.
    • Opportunity Cost: The economic value of a resource in its next-best alternative use. Captures the forgone benefit that could have been realized had that resource been allocated to an alternative project.
  • Analytical Adjustments in Economic Evaluations:
    • Sensitivity Analysis: The systematic variation of key clinical and economic assumptions within plausible ranges to test how sensitive the study's conclusions are to uncertainty.
    • Analysis of Extremes: A technique testing worst-case scenarios (lowest clinical effectiveness paired with highest cost estimates) against best-case scenarios (highest clinical effectiveness paired with lowest cost estimates).
    • Time Value of Money (Discounting): When costs or clinical outcomes extend beyond a 1 year1\text{ year} time horizon, economic evaluations must apply a statutory discount rate to adjust future dollars and outcomes to present value, accounting for inflation and the time preference for money.

Comparative Analysis of the Six Core Pharmacoeconomic Methodologies

  • 1. Cost-Minimization Analysis (CMA):
    • Primary Assumption: Compares two or more therapeutic interventions whose clinical outcomes have been conclusively proven to be therapeutically equivalent in efficacy and safety.
    • Outcome Measurement: Outcomes are assumed identical and are not measured in different units; the analysis focuses exclusively on identifying cost differences.
    • Analytical Purpose: To identify the least costly therapeutic alternative among clinically identical choices (e.g., comparing brand-name drugs to AB-rated generic equivalents, or comparing biosimilars to reference biologics).
    • Methodological Constraint: Equivalence in clinical efficacy and adverse effect profiles must be empirically proven in advance; if clinical outcomes differ, a CMA is invalid and represents an incomplete cost-only analysis.
  • 2. Cost-Benefit Analysis (CBA):
    • Scope: Takes a broad societal, "long view" (future downstream consequences) and "wide view" (collateral systemic effects). Well-suited for broad public health resource allocations (e.g., universal vaccination programs versus mandatory child safety seat legislation).
    • Measurement of Consequences: Both the costs of the intervention and the resulting clinical and health consequences are measured and expressed in monetary terms (dollars, \).
    • Primary Advantage: Because inputs and outcomes are converted into monetary values, CBA allows decision makers to compare completely disparate programs addressing unrelated disease states or public safety priorities.
    • Primary Methodological Challenge: Assigning explicit dollar values to human life, disease prevention, and pain reduction.
    • Methods to Value Human Life and Health Improvements:
    • Human Capital Approach: Estimates the monetary value of health improvements by calculating the future economic earnings a person would generate during their remaining productive working years. Limitations: Ignores non-economic intrinsic value to family and community, and undervalues individuals who do not earn market wages (homemakers, the elderly, the unemployed, and marginalized populations).
    • Willingness-to-Pay (WTP) Approach: Determines value by asking individuals hypothetical contingent valuation questions to elicit the maximum dollar amount they would pay to reduce the risk of illness, pain, or death. Advantages: Captures productivity gains and intangible benefits. Limitations: Relies on an individual's ability to comprehend hypothetical risk scenarios, and responses are skewed by an individual's personal wealth.
    • Formulas for Presenting CBA Results:
    • Net Benefit: Calculated as total monetary benefits minus total costs:       Net Benefit=Total Benefits−Total Costs\text{Net Benefit} = \text{Total Benefits} - \text{Total Costs}       A project is economically desirable if Net Benefit>0\text{Net Benefit} > 0. When choosing between alternatives, select the project yielding the highest net benefit.
    • Benefit-to-Cost Ratio: Calculated as total monetary benefits divided by total monetary costs:       Benefit-to-Cost Ratio=Total BenefitsTotal Costs\text{Benefit-to-Cost Ratio} = \frac{\text{Total Benefits}}{\text{Total Costs}}       A project is economically desirable if the ratio exceeds one (>1> 1). When comparing mutually exclusive programs, select the project with the highest ratio.
    • Cost-to-Benefit Ratio: Calculated as total monetary costs divided by total monetary benefits:       Cost-to-Benefit Ratio=Total CostsTotal Benefits\text{Cost-to-Benefit Ratio} = \frac{\text{Total Costs}}{\text{Total Benefits}}       A project is economically desirable if the ratio is less than one (<1< 1). When comparing programs, select the project with the lowest ratio.
    • Informational Value: Presenting results as net benefit provides clearer, more actionable information to decision makers than ratio analyses alone.
  • 3. Cost-Effectiveness Analysis (CEA):
    • Outcome Measurement: Outcomes are quantified in natural clinical units (e.g., millimeters of mercury [mmHgmmHg] reduction in blood pressure, milligrams per deciliter [mg/dLmg/dL] reduction in cholesterol, percent reduction in HbA1c, or life-years gained).
    • Application: Evaluates interventions whose outcomes are measured on the exact same clinical scale. Used to compare two or more treatment alternatives to determine which option yields the best clinical outcome at the lowest cost.
    • Subjectivity: The determination of whether an intervention is cost-effective is relative (made in comparison to alternative therapies) and subjective (the payer or decision maker must decide whether an incremental gain in clinical efficacy is worth the additional expenditure).
    • Formulas for Presenting CEA Results:
    • Average Cost-Effectiveness Ratio (ACER): Measures the average cost required to produce one unit of clinical effect for a single therapy:       ACER=Total CostTotal Clinical Outcome\text{ACER} = \frac{\text{Total Cost}}{\text{Total Clinical Outcome}}
    • Incremental Cost-Effectiveness Ratio (ICER): Measures the additional economic expenditure required to achieve one additional unit of clinical outcome when comparing one alternative to another:       ICER=ΔCostΔEffect=CostB−CostAOutcomeB−OutcomeA\text{ICER} = \frac{\Delta \text{Cost}}{\Delta \text{Effect}} = \frac{\text{Cost}_B - \text{Cost}_A}{\text{Outcome}_B - \text{Outcome}_A}
    • Budget Impact Analysis (BIA): An analytical model evaluating the net financial impact of introducing a new, cost-effective health technology into a specific healthcare system or managed care plan's formulary over a short-term operational horizon (11 to 5 years5\text{ years}). Managed care plans often require drug manufacturers to submit a BIA alongside a CEA to forecast overall drug spend for a disease population.
  • 4. Cost-Utility Analysis (CUA):
    • Relationship to CEA: A specialized subtype of cost-effectiveness analysis where health outcomes are weighted by patient preference values (utilities) to capture both the quantity and quality of life.
    • Outcome Metric (The QALY): Outcomes are measured in Quality-Adjusted Life Years (QALYs):     QALY=Utility Score×Years of Life Gained\text{QALY} = \text{Utility Score} \times \text{Years of Life Gained}
    • The Utility Scale: Utility weights reflect health-related quality of life on an interval scale from 00 to 11, where 0.00.0 represents death and 1.01.0 represents a state of perfect health. Intermediate health states fall between 00 and 11.
    • Elicitation Tools: Utility scores are elicited directly from patients or surrogate populations using standardized preference instruments, such as the Visual Analog Scale (VAS) (where patients mark their perceived health state along a calibrated line from 00 to 11), time trade-off exercises, or validated questionnaires.
    • Incremental Cost-Utility Ratio (ICUR): Presents the economic evaluation of comparative therapies:     ICUR=ΔCostΔQALYs=CostB−CostAQALYB−QALYA\text{ICUR} = \frac{\Delta \text{Cost}}{\Delta \text{QALYs}} = \frac{\text{Cost}_B - \text{Cost}_A}{\text{QALY}_B - \text{QALY}_A}
  • 5. Cost of Illness (COI) Analysis (Burden of Illness):
    • Scope: Identifies and calculates the total aggregate economic burden generated by a specific disease state across an entire defined geographic population.
    • Cost Components: Combines all direct medical, direct non-medical, and indirect morbidity/mortality costs associated with the prevention, clinical management, and long-term complications of the illness.
    • Application: Does not evaluate or compare the therapeutic efficacy of competing pharmaceutical interventions. Instead, it provides health policy leaders with benchmark data to illustrate the overall economic burden of a disease, supporting the prioritization of biomedical research funding and public health resource allocation.
  • 6. Cost-Consequence Analysis (CCA):
    • Reporting Format: Tabulates all costs and clinical outcomes in a disaggregated, itemized matrix without combining them into composite ratios (such as an ICER or benefit-to-cost ratio).
    • Advantages: Provides comprehensive transparency, enabling diverse stakeholders (such as hospital administrators, self-insured employers, and clinicians) to review the data and select the specific costs and outcomes relevant to their perspective.
    • Disadvantages: Highly complex to construct, and does not provide an integrated summary ratio to offer a clear, definitive recommendation for decision makers.

Pharmacoeconomic Study Designs, Decision Modeling, and Critical Appraisal Standards

  • Primary Pharmacoeconomic Research Designs:
    • Randomized Controlled Trials (RCTs):
    • Patients are prospectively recruited and randomly allocated to competing treatment arms under blinding and strict adherence to a standardized treatment protocol.
    • Advantages: Strong internal validity, minimizing selection bias and confounding to ensure observed differences are attributable to the therapeutic intervention.
    • Disadvantages: High implementation costs, and tightly controlled experimental protocols do not reflect routine real-world clinical practice (low external validity/generalizability).
    • Naturalistic Designs:
    • Patients are randomly assigned to treatment arms, but patient selection criteria and subsequent clinical care mirror routine practice environments.
    • Advantages: Delivers higher external validity than traditional RCTs while maintaining randomization.
    • Disadvantages: Substantially more expensive and operationally complex to administer than observational retrospective studies.
    • Retrospective Database Analyses (Claims Data Studies):
    • Evaluates patient outcomes and healthcare resource utilization using historical observational datasets, such as commercial insurance claims or Medicare Part A, B, and D billing records.
    • Advantages: Accurately reflects real-world clinical care patterns, provides large sample sizes, and requires less execution time and cost than prospective clinical trials.
    • Disadvantages: Datasets often lack granular clinical indicator variables (such as laboratory values, disease severity staging, or pain scores), carry risks of diagnostic coding errors, and report provider billed charges rather than the true underlying economic costs of resource consumption.
  • Decision Analysis and Health Economic Modeling:
    • Core Purpose: A structured approach to clinical and economic decision-making under conditions of uncertainty. Rather than collecting prospective patient-level trial data, modeling synthesizes secondary clinical efficacy literature with economic resource utilization estimates to simulate healthcare problems.
    • Decision Tree Modeling:
    • Used when prospective clinical observation is unfeasible due to time or resource constraints.
    • The expected cost of a therapeutic strategy is determined by summing the probabilities of each clinical event branch multiplied by the cost of managing that event:       Expected Cost=∑(Probability of Event×Cost of Event)\text{Expected Cost} = \sum (\text{Probability of Event} \times \text{Cost of Event})
    • Markov Modeling:
    • Designed to model chronic disease states characterized by cyclical progressions, remissions, and relapses over long time horizons.
    • Models represent health as mutually exclusive "health states" (e.g., well, mild disease, severe illness, dead).
    • Patients transition between health states over defined intervals (cycles) based on transition probabilities. Markov models are preferred when disease risks are continuous, the timing of clinical events is critical, or events recur over a patient's lifetime.
  • Critical Appraisal and Reporting Standards:
    • Methodological Vulnerabilities: A significant proportion of published economic evaluations suffer from flawed designs, such as failure to define the study perspective, omitting relevant cost categories, utilizing unvalidated outcome metrics, or omitting sensitivity analyses.
    • The CHEERS Statement: The Consolidated Health Economic Evaluation Reporting Standards (CHEERS) guidelines, developed by the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Task Force, establishes reporting requirements to ensure transparency and consistency in published health economic studies.
    • CHEERS Evaluation Domains: Establishes essential reporting criteria across six structural domains:
    • Title and abstract
    • Introduction
    • Methods
    • Results
    • Discussion
    • Other (declarations of funding, study perspective, and conflicts of interest)

Transcribed Background Dialogue and Exchanges

  • Exchange Regarding Demands and the Colony House:
    • Question/Prompt: "What's going on? You guys are gonna stand there and make demands? Don't what you…"
    • Response: "Those things got in the colony house."
  • Exchange Regarding Victor:
    • Question/Prompt: "Aren't you the guys that thought this… Fuck off. The 1935 Social Security Act marks the beginning of the federal government's involvement in social insurance. And you guys know Victor?"
    • Response: Unanswered interjection during lecture transition.
  • Exchange Regarding the Screening and Hole:
    • Question/Prompt: "When the screening started, we climbed out…"
    • Response: "We're digging a hole for you."
  • Verbal Confrontation:
    • Prompt: "Just stay the fuck away from my daughter. You understand me?"
    • Response: (No direct verbal reply recorded; lecture resumed regarding star ratings).
  • Exchange During Discussion of Disability Eligibility:
    • Prompt: "Drive away. No. No. No. Please."
    • Response: (No direct verbal reply recorded; lecture resumed regarding ALS exception).
  • Audience Exchange on Program Enrollment:
    • Prompt: "A bit of difference if they bind us."
    • Response: "You all have questions."
  • Exchange Regarding Assistance:
    • Question/Prompt: "Yeah. Of course… Yeah. I'll try to check it out… Let me know when you go into the rest… But that… That's not why I'm here. We came because we need your help."
    • Response: "Say what?"
    • Follow-up: "We we we… We can't. And we already got a strong indication that this could work."
    • Response: "You're okay with this?"
  • Exchange Regarding Clinical Understanding:
    • Prompt: "Do what? I understand."
    • Response: (No direct verbal reply recorded; lecture resumed regarding benefit periods).
  • Exchange Regarding SNF Care Constraints:
    • Prompt: "That's what you people do. Really not much of… Is what you see. Doesn't give us much time for anything. Out for each other, taking care of each other. And then you build…"
    • Response: (No direct verbal reply recorded; lecture resumed regarding home health visits).
  • Exchange on Personal Inquiries:
    • Prompt: "What are you doing? Finally… Anything… Second… Don't have an answer for you right now."
    • Response: "Simple question."
  • Exchange Regarding Status Check:
    • Prompt: "Said you had to go… No. Good morning."
    • Response: "We're Okay? We're not done."
  • Exchange on Departing:
    • Prompt: "To go home? We might as well swallow fucking bowling right now. Let's take a walk. I'm just getting on the way."
    • Response: "In the fourth? Yep."
  • Exchange on Food and Conversations:
    • Prompt: "Hey. Look. I need to talk to you. Alright. Hey. Could you take one bite of this?"
    • Response: "No. Yeah. No. You got it. Yeah. Yeah. No. We got some…"
  • Family Dialogue Regarding Searching:
    • Prompt: "Okay. So then why don't we just get someone else to go and look for a while?"
    • Response: "Dad, we need you here. Mom needs you here… To what I'm saying to you. Chrissy. Chrissy."
  • Exchange Regarding Activity:
    • Prompt: "What do you do? I love the Christmas stuff. Look at them."
    • Response: "He has nothing to do. He's a cat."